Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and ch...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis Group
2023-06-01
|
| Reeks: | CNS Oncology |
| Onderwerpen: | |
| Online toegang: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0017 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|